Investigating the effect of moxifloxacin in Helicobacter infectio

Phase 3

• Conditions: Helicobacter pylori infection.; Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters; B98.0

• Registration Number: IRCT20240128060832N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 246

Inclusion Criteria

Age above 18 years
All patients with PUD, peptic ulcer, non-ulcer dyspepsia and intestinal metaplasia (based on pathology samples) underwent endoscopic evaluation and H. pylori positive confirmation by Rapid urease test (RUT).
No previous treatment of H. pylori infection
Patient consent to participate in the study

Exclusion Criteria

Unwillingness to participate in the study
Taking antibiotics or non-steroidal anti-inflammatory drugs (NSAID) in the last 4 weeks
Allergy to any of the study drugs
A history of gastric surgery or the presence of a serious concurrent disease such as cancer
Pregnant or lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of positive or negative Helicobacter infection by fecal antigen test. Timepoint: Helicobacter test before and two weeks after treatment. Method of measurement: Helicobacter pylori fecal antigen.

Secondary Outcome Measures

Name	Time	Method
Drug side effects. Timepoint: During treatment and two weeks after treatment. Method of measurement: Registration in the patient's self-report questionnaire.;Acceptance of medication. Timepoint: During treatment and two weeks after treatment. Method of measurement: Registration in the patient's self-report questionnaire.